Gilead Sciences Given Consensus Recommendation of “Buy” by Analysts (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) has been given a consensus rating of “Buy” by the twenty-six brokerages that are currently covering the stock, American Banking News.com reports. One analyst has rated the stock with a hold rating and twenty-one have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $105.55.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 103.96 on Tuesday. Gilead Sciences has a one year low of $58.50 and a one year high of $105.16. The stock’s 50-day moving average is $92. and its 200-day moving average is $82.00. The company has a market cap of $157.2 billion and a price-to-earnings ratio of 23.17.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.00 EPS for the current fiscal year.
In other Gilead Sciences news, CFO Robin L. Washington sold 33,556 shares of the company’s stock on the open market in a transaction dated Thursday, August 14th. The stock was sold at an average price of $95.56, for a total transaction of $3,206,611.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
GILD has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.